SI3538525T1 - 3-substituirane propionske kisline kot inhibitorji alfa v integrina - Google Patents

3-substituirane propionske kisline kot inhibitorji alfa v integrina

Info

Publication number: SI3538525T1
Authority: SI; Slovenia
Prior art keywords: alpha; propionic acids; integrin inhibitors; substituted propionic; substituted
Prior art date: 2016-11-08

Application number

SI201731195T

Other languages

English (en)

Inventor

Guohua Zhao

Pratik Devasthale

Xiang-Yang Ye

Kumaravel Selvakumar

Suresh Dhanusu

Palanikumar Balasubramanian

Leatte R. Guernon

Rita Civiello

Xiaojun Han

Michael F. Parker

Swanee E. Jacutin-Porte

Original Assignee

Bristol-Myers Squibb Company

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-11-08

Filing date

2017-11-07

Publication date

2022-09-30

2017-11-07 Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company

2022-09-30 Publication of SI3538525T1 publication Critical patent/SI3538525T1/sl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SI201731195T 2016-11-08 2017-11-07 3-substituirane propionske kisline kot inhibitorji alfa v integrina SI3538525T1 (sl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201662418848P	2016-11-08	2016-11-08
PCT/US2017/060376 WO2018089353A1 (en)	2016-11-08	2017-11-07	3-substituted propionic acids as alpha v integrin inhibitors
EP17801230.8A EP3538525B1 (en)	2016-11-08	2017-11-07	3-substituted propionic acids as alpha v integrin inhibitors

Publications (1)

Publication Number	Publication Date
SI3538525T1 true SI3538525T1 (sl)	2022-09-30

Family

ID=60409432

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SI201731195T SI3538525T1 (sl)	2016-11-08	2017-11-07	3-substituirane propionske kisline kot inhibitorji alfa v integrina

Country Status (29)

Country	Link
US (2)	US10968219B2 (sl)
EP (1)	EP3538525B1 (sl)
JP (1)	JP7097358B2 (sl)
KR (1)	KR102505629B1 (sl)
CN (1)	CN110167935B (sl)
AR (1)	AR110153A1 (sl)
AU (1)	AU2017359023B2 (sl)
CA (1)	CA3042707A1 (sl)
CL (1)	CL2019001264A1 (sl)
CO (1)	CO2019005824A2 (sl)
DK (1)	DK3538525T3 (sl)
EA (1)	EA038164B1 (sl)
ES (1)	ES2925173T3 (sl)
HR (1)	HRP20220990T1 (sl)
HU (1)	HUE059708T2 (sl)
IL (1)	IL266473B (sl)
LT (1)	LT3538525T (sl)
MA (1)	MA46743A (sl)
MX (1)	MX380799B (sl)
MY (1)	MY199931A (sl)
PE (1)	PE20191647A1 (sl)
PL (1)	PL3538525T3 (sl)
PT (1)	PT3538525T (sl)
RS (1)	RS63483B1 (sl)
SI (1)	SI3538525T1 (sl)
SM (1)	SMT202200338T1 (sl)
TW (1)	TWI763733B (sl)
WO (1)	WO2018089353A1 (sl)
ZA (1)	ZA201903665B (sl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3509590A4 (en)	2016-09-07	2020-12-02	Pliant Therapeutics, Inc.	N-ACYL AMINO ACID COMPOUNDS AND METHOD OF USING
ES2898835T3 (es) *	2016-11-08	2022-03-09	Bristol Myers Squibb Co	Azol amidas y aminas como inhibidores de la integrina alfav
BR112019009129A2 (pt) *	2016-11-08	2019-07-16	Bristol-Myers Squibb Company	compostos mono e espirocíclicos contendo ciclobutano e azetidina como inibidores de alfa v integrina
US10968219B2 (en) *	2016-11-08	2021-04-06	Bristol-Myers Squibb Company	3-substituted propionic acids as αV integrin inhibitors
CA3045491A1 (en)	2016-12-29	2018-07-19	Indalo Therapeutics, Inc.	Integrin antagonists
CA3054792A1 (en)	2017-02-28	2018-09-07	Morphic Therapeutic, Inc.	Inhibitors of .alpha.v.beta.6 integrin
JP7092784B2 (ja)	2017-02-28	2022-06-28	モーフィックセラピューティック，インコーポレイテッド	αｖβ６インテグリン阻害剤
CA3109534A1 (en)	2018-08-29	2020-03-05	Morphic Therapeutic, Inc.	Inhibiting .alpha.v .beta.6 integrin
FI3873884T3 (fi)	2018-10-30	2025-02-24	Gilead Sciences Inc	3-(kinolin-8-yyli)-1,4-dihydropyrido[3,4-d]pyrimidiini-2,4-dionijohdannaisia alfa-4-beta-7-integriinin estäjinä tulehdussairauksien hoidossa
US11179383B2 (en)	2018-10-30	2021-11-23	Gilead Sciences, Inc.	Compounds for inhibition of α4β7 integrin
JP7189368B2 (ja)	2018-10-30	2022-12-13	ギリアードサイエンシーズ，インコーポレイテッド	アルファ４ベータ７インテグリンの阻害のための化合物
JP7214882B2 (ja)	2018-10-30	2023-01-30	ギリアードサイエンシーズ，インコーポレイテッド	アルファ４ベータ７インテグリン阻害剤としてのイミダゾピリジン誘導体
CN109824495B (zh) *	2019-02-02	2022-12-09	盐城师范学院	一种新型偶联反应在制备碳-碳键结构化合物中的应用
CN119431230A (zh)	2019-08-14	2025-02-14	吉利德科学公司	用于抑制α4β7整合素的化合物
GB202010626D0 (en)	2020-07-10	2020-08-26	Univ Nottingham	Compound

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0451790A1 (de) *	1990-04-12	1991-10-16	Hoechst Aktiengesellschaft	3,5-disubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu deren Herstellung, diese enthaltende Mittel und ihre Verwendung
US5849736A (en)	1993-11-24	1998-12-15	The Dupont Merck Pharmaceutical Company	Isoxazoline and isoxazole fibrinogen receptor antagonists
ZA972195B (en)	1996-03-15	1998-09-14	Du Pont Merck Pharma	Spirocycle integrin inhibitors
EP1049693A1 (en)	1997-11-26	2000-11-08	Du Pont Pharmaceuticals Company	1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS $g(a) v?$g(b) 3? ANTAGONISTS
JP2002508323A (ja) *	1997-12-17	2002-03-19	メルクエンドカムパニーインコーポレーテッド	インテグリン受容体拮抗薬
CA2338878A1 (en)	1998-08-13	2000-02-24	Merck & Co., Inc.	Integrin receptor antagonists
MXPA03006772A (es)	2001-01-29	2004-10-15	Dimensional Pharm Inc	Indoles sustituidos y su uso como antogonistas de integrina.
MXPA05006588A (es) *	2002-12-20	2005-08-16	Pharmacia Corp	Compuestos de pirazol como derivados antagonistas del receptor de la integrina.
MXPA05006727A (es) *	2002-12-20	2005-09-08	Pharmacia Corp	Acidos heteroarilalcanoicos como antagonistas de receptor de integrina.
WO2006108040A1 (en)	2005-04-05	2006-10-12	Janssen Pharmaceutica, N.V.	Substituted indoles and their use as integrin antagonists
TW200800999A (en) *	2005-09-06	2008-01-01	Astrazeneca Ab	Novel compounds
US7592461B2 (en)	2005-12-21	2009-09-22	Bristol-Myers Squibb Company	Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
AR059224A1 (es)	2006-01-31	2008-03-19	Jerini Ag	Compuestos para la inhibicion de integrinas y uso de estas
EP2049490A1 (en) *	2006-06-09	2009-04-22	Astra Zeneca AB	N-(benzoyl)-o- [2- (pyridin- 2 -ylamino) ethyl]-l-tyrosine derivatives and related compounds as a5b1 antagonists for the treatment of solid tumors
WO2008125811A1 (en) *	2007-04-11	2008-10-23	Astrazeneca Ab	N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
CN102482225B (zh)	2009-09-04	2016-10-05	巴斯夫欧洲公司	制备1-苯基吡唑类的方法
ES2574927T3 (es)	2009-10-29	2016-06-23	Glaxosmithkline Llc	Piridinas bicíclicas y análogos como moduladores de sirtuina
ITFI20100019A1 (it)	2010-02-12	2011-08-13	Univ Firenze	Inibitori peptidomimetici di integrine basati sull'1,2,3-triazolo per la diagnosi e terapia dei tumori.
GB201305668D0 (en)	2013-03-28	2013-05-15	Glaxosmithkline Ip Dev Ltd	Avs6 Integrin Antagonists
TWI667233B (zh)	2013-12-19	2019-08-01	德商拜耳製藥公司	新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
GB201417002D0 (en)	2014-09-26	2014-11-12	Glaxosmithkline Ip Dev Ltd	Novel compound
GB201417018D0 (en)	2014-09-26	2014-11-12	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201417011D0 (en)	2014-09-26	2014-11-12	Glaxosmithkline Ip Dev Ltd	Novel compounds
GB201417094D0 (en)	2014-09-26	2014-11-12	Glaxosmithkline Ip Dev Ltd	Novel compounds
TWI736529B (zh)	2015-02-19	2021-08-21	美商賽氟洛生命科學公司	氟化之四氫啶基壬酸衍生物及其用途
US10214522B2 (en) *	2015-03-10	2019-02-26	The Regents Of The University Of California	Anti-alphavbeta1 integrin inhibitors and methods of use
US10968219B2 (en) *	2016-11-08	2021-04-06	Bristol-Myers Squibb Company	3-substituted propionic acids as αV integrin inhibitors

2017
- 2017-11-07 US US16/347,844 patent/US10968219B2/en active Active
- 2017-11-07 PL PL17801230.8T patent/PL3538525T3/pl unknown
- 2017-11-07 WO PCT/US2017/060376 patent/WO2018089353A1/en active Application Filing
- 2017-11-07 MY MYPI2019002576A patent/MY199931A/en unknown
- 2017-11-07 PE PE2019000940A patent/PE20191647A1/es unknown
- 2017-11-07 DK DK17801230.8T patent/DK3538525T3/da active
- 2017-11-07 ES ES17801230T patent/ES2925173T3/es active Active
- 2017-11-07 MX MX2019005244A patent/MX380799B/es unknown
- 2017-11-07 JP JP2019523576A patent/JP7097358B2/ja active Active
- 2017-11-07 CN CN201780082473.2A patent/CN110167935B/zh active Active
- 2017-11-07 HU HUE17801230A patent/HUE059708T2/hu unknown
- 2017-11-07 RS RS20220759A patent/RS63483B1/sr unknown
- 2017-11-07 SM SM20220338T patent/SMT202200338T1/it unknown
- 2017-11-07 PT PT178012308T patent/PT3538525T/pt unknown
- 2017-11-07 SI SI201731195T patent/SI3538525T1/sl unknown
- 2017-11-07 KR KR1020197016082A patent/KR102505629B1/ko active Active
- 2017-11-07 AU AU2017359023A patent/AU2017359023B2/en active Active
- 2017-11-07 MA MA046743A patent/MA46743A/fr unknown
- 2017-11-07 CA CA3042707A patent/CA3042707A1/en active Pending
- 2017-11-07 HR HRP20220990TT patent/HRP20220990T1/hr unknown
- 2017-11-07 EA EA201991122A patent/EA038164B1/ru unknown
- 2017-11-07 EP EP17801230.8A patent/EP3538525B1/en active Active
- 2017-11-07 LT LTEPPCT/US2017/060376T patent/LT3538525T/lt unknown
- 2017-11-08 AR ARP170103105A patent/AR110153A1/es unknown
- 2017-11-08 TW TW106138533A patent/TWI763733B/zh active
2019
- 2019-05-06 IL IL266473A patent/IL266473B/en unknown
- 2019-05-08 CL CL2019001264A patent/CL2019001264A1/es unknown
- 2019-06-04 CO CONC2019/0005824A patent/CO2019005824A2/es unknown
- 2019-06-07 ZA ZA2019/03665A patent/ZA201903665B/en unknown
2021
- 2021-02-24 US US17/184,179 patent/US11884661B2/en active Active

Also Published As

Publication number	Publication date
AU2017359023B2 (en)	2021-12-09
KR102505629B1 (ko)	2023-03-02
US11884661B2 (en)	2024-01-30
MA46743A (fr)	2019-09-18
IL266473A (en)	2019-07-31
IL266473B (en)	2022-06-01
CA3042707A1 (en)	2018-05-17
RS63483B1 (sr)	2022-09-30
DK3538525T3 (da)	2022-08-29
MY199931A (en)	2023-11-29
CO2019005824A2 (es)	2019-06-11
LT3538525T (lt)	2022-09-26
ES2925173T3 (es)	2022-10-14
TW201823244A (zh)	2018-07-01
PL3538525T3 (pl)	2022-09-12
US10968219B2 (en)	2021-04-06
WO2018089353A1 (en)	2018-05-17
PE20191647A1 (es)	2019-11-07
MX2019005244A (es)	2019-08-05
EP3538525A1 (en)	2019-09-18
EA038164B1 (ru)	2021-07-16
AU2017359023A1 (en)	2019-06-20
HUE059708T2 (hu)	2022-12-28
JP2019537594A (ja)	2019-12-26
EA201991122A1 (ru)	2019-10-31
CL2019001264A1 (es)	2019-09-13
CN110167935A (zh)	2019-08-23
US20190263808A1 (en)	2019-08-29
KR20190073554A (ko)	2019-06-26
PT3538525T (pt)	2022-08-16
MX380799B (es)	2025-03-12
SMT202200338T1 (it)	2022-09-14
US20210188847A1 (en)	2021-06-24
HRP20220990T1 (hr)	2022-11-11
AR110153A1 (es)	2019-02-27
ZA201903665B (en)	2022-12-21
CN110167935B (zh)	2022-05-27
JP7097358B2 (ja)	2022-07-07
EP3538525B1 (en)	2022-06-22
TWI763733B (zh)	2022-05-11

Publication	Publication Date	Title
ZA201903665B (en)	2022-12-21	3-substituted propionic acids as alpha v integrin inhibitors
HRP20192119T8 (hr)	2020-08-21	Pripravak i metoda za pomoć pri spavanju
EP3193608A4 (en)	2018-05-02	Carm1 inhibitors and uses thereof
EP3200588A4 (en)	2018-04-25	Arginine methyltransferase inhibitors and uses thereof
EP3193611A4 (en)	2018-02-28	Mk2 inhibitors and uses thereof
EP3134536A4 (en)	2017-12-20	Systems and methods for barcoding nucleic acids
EP3190682A4 (en)	2018-08-29	Power supply system and method
IL267239A (en)	2019-08-29	New derivatives of phenylpropionic acid and their uses
PL3218378T3 (pl)	2020-10-19	Pochodne 6-amino-7-bicyklo-7-deazapuryny jako inhibitory kinaz białkowych
EP3181085A4 (en)	2018-04-04	Tracking system and tracking method using same
EP3238840A4 (en)	2018-05-30	Method for recycling used absorbent article
EP3141930A4 (en)	2017-12-27	Distance-measurement device and method for powering distance-measurement device
EP3166523A4 (en)	2018-03-14	Cryoablation method and system
EP3397430A4 (en)	2020-04-22	HEAD SUPPORT SYSTEMS AND METHODS OF USE
EP3195129A4 (en)	2018-05-02	Application centric distributed storage system and method
IL255054A0 (en)	2017-12-31	Tetrahydronephthyridinyl propionic acid derivatives and their uses
EP3232039A4 (en)	2018-07-11	Method and device for energy-saving ship navigation
HK1243443A1 (zh)	2018-07-13	C1酯酶抑制劑融合蛋白及其用途
EP3185880A4 (en)	2018-07-04	Improved peptidyl calcineurin inhibitors
EP3139918A4 (en)	2018-05-09	Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors
EP3209675A4 (en)	2018-04-18	Compositions and methods for the detection of nucleic acids
EP3217932A4 (en)	2018-05-16	Surgical articles and methods for detection
EP3176097A4 (en)	2018-09-19	Blank supply device and blank supply method using same
EP3097101A4 (en)	2017-06-07	Isoquinoline derivatives as mgat2 inhibitors
EP3094615A4 (en)	2017-11-08	Terpene-derived acids and esters and methods for preparing and using same